Pediatric sepsis and multiple organ dysfunction syndrome

Current Opinion in Pediatrics

Volumn 13, Issue 3, 2001, Pages 247-253

  Despond, Olivier ^a   Proulx, François ^a   Carcillo, Joseph A ^b   Lacroix, Jacques ^a,c  

^a UNIVERSITY OF MONTREAL   (Canada)

^b Pediatric Critical Care Medicine   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; ENDOTOXIN ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROCALCITONIN; PROTEIN C; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL EXAMINATION; DIET THERAPY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; MULTIPLE ORGAN FAILURE; NUTRITIONAL SUPPORT; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0034981305     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200106000-00006     Document Type: Review

References (68)

1. Timing and predictors of death in pediatric multiple organ system failure
2. Epidemiology of sepsis and multiple organ dysfunction syndrome in children
3. A comparison of risks and outcomes for patients with organ system failure: 1982-1990
4. Sepsis and multiple organ dysfunction syndrome: A clinical-mechanistic overview
5. Proinfiammatory cytokines
6. Balancing the inflammatory response in sepsis
7. Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 are increased in the plasma of children with sepsis-induced multiple organ failure
8. Increased rigidity and priming of polymorphonuclear leukocytes in sepsis
9. Nitric oxide production in meningococcal disease is directly related to disease severity
10. Microcirculatory oxygenation and shunting in sepsis and shock
11. Increased intestinal permeability is associated with the development of multiple organ dysfunction syndrome in critically ill ICU patients
12. The role of apoptosis in the immune system
13. Does programmed cell death (apoptosis) play a role in the development of multiple organ dysfunction in critically ill patients? A review and a theoretical framework
14. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction
15. Potential risk factors for developing apoptosis during septic shock
16. Inappropriate sympathetic activation at onset of septic shock
17. Experimental human endotoxemia increases cardiac regularity: Results from a prospective, randomized crossover trial
18. Linear and nonlinear analysis of hemodynamic signals during sepsis and septic shock
19. Multiple organ dysfunction syndrome: Exploring the paradigm of complex nonlinear system
20. Microbial infection and the septic response in critical surgical illness
21. Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury
22. Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients
23. Rapid diagnostic methods in the detection of sepsis
24. Diagnostic markers of infection: Comparison of procalcitonin with C reactive protein and leukocyte count
25. Intérét de la procalcitonine, nouveau marqueur de l'infection bactérienne
26. Procalcitonin as a marker of bacterial infection
27. Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-alpha and interleukin-6 in patients with sepsis
28. Sepsis and the systemic inflammatory response syndrome: Neuromuscular manifestations
29. Reactive hemophagocytic syndrome presenting as a component of multiple organ system failure
30. Myopathy in critically ill patients
31. Hemophagocytic lymphohistiocytic syndrome: Unrecognized cause of multiple organ failure
32. Hidden inflammatory potential of the red blood cell
33. Transfusion requirements in critical care investigators, for the Canadian Critical Care Trials Group: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care
34. Development of a pediatric multiple organ dysfunction score: Use of two strategies
35. MODS as predictor outcome: European perspective
36. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial
37. Plasma nitrite and nitrate concentrations and multiple organ failure in pediatric sepsis
38. Protein C leveis as a prognostic indicator of outcome in sepsis and related diseases
39. Procalcitonin and cytokine levels: Relation to organ failure and mortality in pediatric shock
40. Variation in PAI-1 gene and risk of meningoccoccal septic shock
41. Plasmafiltration in sepsis: Removing the evil humors
42. Continuous plasma filtration in sepsis syndrome
43. Evaluation of oxygen consumption and resting energy expenditure in critically ill patients with systemic inflammatory response syndrome
44. An immune-enhancing enteral diet reduces mortality rate and episodes of bacteremia in septic intensive care unit patients
45. A prospective, randomized, double-blind, controlled clinical trial of enteral immunonutrition in the critically ill
46. Immunonutrition in the critically ill: A systematic review of clinical outcome
47. Immunonutrition comes of age
48. Selenium, systemic immune response syndrome, sepsis, and outcome in critically ill patients
49. Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome
50. Intravenous immunoglobulin for treating sepsis and septic shock
51. Molecular biology of septic shock
52. Treatment of septic shock with human monoclonal antibody HA-1A
53. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin
54. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock
55. A randomized, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates
56. Impact of colony-stimulating factor therapy on clinical outcome and frequency rate of nosocomial infections in intensive care unit neutropenic patients
57. Roundtable I: Relationships between coagulation and inflammatory processes
58. Pathophysiology of disseminated intravascular coagulation in sepsis
59. Clinical trial results with antithrombin III in sepsis
60. Use of protein-C concentrate, heparin and haemofiltration in meningococcus-induced purpura fulminans
61. Treatment of purpura fulminans in meningoccocemia with protein C concentrate
62. Protein C substitution in sepsis-associated purpura fulminans
63. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis
64. Search for effective immunomodulating strategies against sepsis
65. Report of the Committee on Infectious Diseases
66. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis